• 1
    Pietrangelo A. Hereditary hemochromatosis – a new look at an old disease. N Engl J Med 2004; 350: 238397.
  • 2
    Beutler E, Bothwell TH, Charlton RW, Motulsky AG. Hereditary hemochromatosis. In: ScriverCR, BeaudetAL, SlyWS, ValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill, 2001; 312762.
  • 3
    Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399408.
  • 4
    Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. Eur Heart J 1991; 12: 22430.
  • 5
    Click RL, Olson LJ, Edwards WD et al. Echocardiography and systemic diseases. J Am Soc Echocardiogr 1994; 7: 20116.
  • 6
    Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vasc Health Risk Manag 2007; 3: 78395.
  • 7
    Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46: 107180.
  • 8
    Van Der AD, Rovers MM, Grobbee DE et al. Mutations in the HFE gene and cardiovascular disease risk. An individual patient data meta-analysis of 53 880 subjects. Circ Cardiovasc Genet 2008; 1: 4350.
  • 9
    Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999; 99: 8524.
  • 10
    Peterlin B, Globocnik PM, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. J Hum Genet 2003; 48: 6469.
  • 11
    Moczulski DK, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 2001; 24: 118791.
  • 12
    Oliva R, Novials A, Sanchez M et al. The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. Endocrine 2004; 24: 1114.
  • 13
    Davis TM, Beilby J, Davis WA et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2008; 31: 1795801.
  • 14
    Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 2005; 68: 2636.
  • 15
    Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005; 12: 1161208.
  • 16
    Piperno A, Trombini P, Gelosa M et al. Increased serum ferritin is common in men with essential hypertension. J Hypertens 2002; 20: 15138.
  • 17
    Failla M, Giannattasio C, Piperno A et al. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology 2000; 32: 56973.
  • 18
    Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299308.
  • 19
    Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23: 6206.
  • 20
    Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 14059.
  • 21
    Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 29149.
  • 22
    Dahlof B, Devereux R, De Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 70513.
  • 23
    Dahlof B, Devereux RB, Julius S et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32: 98997.
  • 24
    Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 9951003.
  • 25
    Appleyard M, Tybjærg Hansen A, Jensen G, Schnohr P, Nyboe J. The Copenhagen City Heart Study: Østerboundersøgelsen: a book of tables with data from the first examination (1976–78) and a five year follow up (1981–1983). Scand J Soc Med Suppl 1989; 41: 1160.
  • 26
    Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study – tables with data from the third examination 1991–1994. Eur Heart J Suppl 2001; 3: 183.
  • 27
    Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A. Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension 2001; 37: 87581.
  • 28
    Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960; 21: 116075.
  • 29
    Baty D, Terron KA, Mechan D, Harris A, Pippard MJ, Goudie D. Development of a multiplex ARMS test for mutations in the HFE gene associated with hereditary haemochromatosis. J Clin Pathol 1998; 51: 734.
  • 30
    Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41: 20710.
  • 31
    Levy D, Ehret GB, Rice K et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41: 67787.
  • 32
    Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 2007; 13: 492530.
  • 33
    Wall JD, Pritchard JK. Haplotype blocks and linkage disequilibrium in the human genome. Nat Rev Genet 2003; 4: 58797.
  • 34
    Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 22130.
  • 35
    Smith BC, Gorve J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 16959.
  • 36
    George DK, Goldwurm S, MacDonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 3118.
  • 37
    Vari IS, Balkau B, Kettaneh A et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2007; 30: 1795801.
  • 38
    Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 24228.
  • 39
    Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349: 957.
  • 40
    Deugnier Y, Brissot P, Loreal O. Iron and the liver: update 2008. J Hepatol 2008; 48 Suppl. 1: S11323.
  • 41
    Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 14261.